Drugs that contain Methylnaltrexone Bromide
1. List of Relistor drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8552025 | SALIX PHARMS | Stable methylnaltrexone preparation |
Apr, 2024
(1 year, 2 months from now) | |
| US10376584 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(1 year, 2 months from now) | |
| US9669096 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(1 year, 2 months from now) | |
| US8420663 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US9492445 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US8822490 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US9180125 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US8247425 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Dec, 2030
(7 years from now) | |
Market Authorisation Date: 24 April, 2008
Treatment: Treatment of opioid-induced constipation
Dosage: SOLUTION;SUBCUTANEOUS
2. List of Relistor drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420663 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US9180125 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US9724343 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US9492445 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
| US9314461 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(8 years from now) | |
| US8524276 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(8 years from now) | |
| US8956651 | SALIX | Oral formulations and lipophilic salts of methylnal trexone |
Mar, 2031
(8 years from now) | |
| US10376505 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(8 years from now) | |
| US10307417 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(8 years from now) | |
Market Authorisation Date: 19 July, 2016
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic